Global Constipation Treatment

Constipation Treatment Comprehensive Study by Application (Infants, Children), Medication (Opioids, Vitamin Supplements, Antiemetics, Drugs, Antacids, Diuretics), Constipation (Normal Transit Constipation, Slow Transit Constipation, Dyssynergic Constipation) Players and Region - Global Market Outlook to 2030

Constipation Treatment Market by XX Submarkets | Forecast Years 2024-2030 | CAGR: 6.8%  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
About Constipation Treatment
Constipation means having a bowel movement less than thrice in a week. It is a common side effect of all opioids. In many cases of constipation treatment, constipation resolves itself without any treatment. The majorly adopted treatment is lifestyle changes including more exercise, having more fiber, and drinking more water. Generally, Laxatives are the most successful treatments of constipation.

AttributesDetails
Study Period2018-2030
Base Year2023
High Growth MarketAsia Pacific
UnitValue (USD Million)
CAGR6.8%


The global Constipation treatment market is highly competitive and consists of some key players. In terms of market share, few of the key players presently dominate the global market. These market players are leveraging on strategic collaborative creativities to intensification their market share and escalation their profitability. Analyst at AMA Research estimates that Global Players will contribute the maximum growth to Global Constipation Treatment market throughout the forecasted period. Established and emerging Players should take a closer view at their existing organizations and reinvent traditional business and operating models to adapt to the future.

AstraZeneca (United Kingdom), Bayer AG (Germany), Sanofi (France), Sucampo Pharmaceuticals, Inc. (United States), Takeda Pharmaceuticals Company Limited (India), Ironwood Pharmaceuticals, Inc. (United States), Bausch Health (Canada), Abbott Laboratories (United States), Cosmo Pharmaceuticals NV (Ireland) and Synergy Pharmaceuticals, Inc. (United States) are some of the key players that are part of study coverage. Additionally, the Players which are also part of the research coverage are Prestige Brands Holdings, Inc. (United States), Janssen Pharmaceutical Company (Belgium) and Shionogi & Co., Ltd. (Japan).

Segmentation Overview
AMA Research has segmented the market of Global Constipation Treatment market by , Application (Infants and Children) and Region.



On the basis of geography, the market of Constipation Treatment has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). North America region held largest market share in the year 2023. If we see Market by Medication, the sub-segment i.e. Opioids will boost the Constipation Treatment market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by Constipation, the sub-segment i.e. Normal Transit Constipation will boost the Constipation Treatment market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.

Influencing Trend:
Increasing Adoption of Laxatives Treatment Type and Increase Adoption of Non-Prescription Drugs for Constipation Treatment

Market Growth Drivers:
Growing Unhygienic Lifestyle in Developed Countries and Growing Number of Fast-Food Outlets across the Globe

Challenges:
Less Awareness about Diagnosis and Treatment Methods for Chronic Idiopathic Constipation

Restraints:
Popularity Of Over the Counter (OTD) Drugs Has Restrains the Market

Opportunities:
Emerging Economies Opening New Opportunities for Market and Growing Incidences of Functional Constipation across the Globe

Market Leaders and their expansionary development strategies
In 2022, Ardelyx, Inc. has been awarded the US Food and Drug Administration (USFDA) for IBSRELA. It is an NHE3 inhibitor for the treatment of irritable bowel syndrome (IBS-C) with constipation in adults.
In 2022, EA Pharma and Mochida Pharmaceutical have launched MOVICOL HD, a chronic constipation treatment, in Japan.
In Dec 2018, the United States Food and Drug Administration announced the approval of prucalopride drug for the treatment of adults with chronic idiopathic constipation. This Chronic condition is affecting around 35 million United States adults.

Key Target Audience
Venture Capitalists and Private Equity Firms, New Entrants/Investors, Analysts and Strategic Business Planners, Constipation treatment drugs Manufacturers, Suppliers and Distributors, Government Regulatory and Research Organizations and End-Use Industries

About Approach
To evaluate and validate the market size various sources including primary and secondary analysis is utilized. AMA Research follows regulatory standards such as NAICS/SIC/ICB/TRCB, to have a better understanding of the market. The market study is conducted on basis of more than 200 companies dealing in the market regional as well as global areas with the purpose to understand the companies positioning regarding the market value, volume, and their market share for regional as well as global.

Further to bring relevance specific to any niche market we set and apply a number of criteria like Geographic Footprints, Regional Segments of Revenue, Operational Centres, etc. The next step is to finalize a team (In-House + Data Agencies) who then starts collecting C & D level executives and profiles, Industry experts, Opinion leaders, etc., and work towards appointment generation.

The primary research is performed by taking the interviews of executives of various companies dealing in the market as well as using the survey reports, research institute, and latest research reports. Meanwhile, the analyst team keeps preparing a set of questionnaires, and after getting the appointee list; the target audience is then tapped and segregated with various mediums and channels that are feasible for making connections that including email communication, telephonic, skype, LinkedIn Group & InMail, Community Forums, Community Forums, open Survey, SurveyMonkey, etc.

Report Objectives / Segmentation Covered

By Application
  • Infants
  • Children
By Medication
  • Opioids
  • Vitamin Supplements
  • Antiemetics
  • Drugs
  • Antacids
  • Diuretics

By Constipation
  • Normal Transit Constipation
  • Slow Transit Constipation
  • Dyssynergic Constipation

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Growing Unhygienic Lifestyle in Developed Countries
      • 3.2.2. Growing Number of Fast-Food Outlets across the Globe
    • 3.3. Market Challenges
      • 3.3.1. Less Awareness about Diagnosis and Treatment Methods for Chronic Idiopathic Constipation
    • 3.4. Market Trends
      • 3.4.1. Increasing Adoption of Laxatives Treatment Type
      • 3.4.2. Increase Adoption of Non-Prescription Drugs for Constipation Treatment
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Constipation Treatment, by Application, Medication, Constipation and Region (value) (2018-2023)
    • 5.1. Introduction
    • 5.2. Global Constipation Treatment (Value)
      • 5.2.1. Global Constipation Treatment by: Application (Value)
        • 5.2.1.1. Infants
        • 5.2.1.2. Children
      • 5.2.2. Global Constipation Treatment by: Medication (Value)
        • 5.2.2.1. Opioids
        • 5.2.2.2. Vitamin Supplements
        • 5.2.2.3. Antiemetics
        • 5.2.2.4. Drugs
        • 5.2.2.5. Antacids
        • 5.2.2.6. Diuretics
      • 5.2.3. Global Constipation Treatment by: Constipation (Value)
        • 5.2.3.1. Normal Transit Constipation
        • 5.2.3.2. Slow Transit Constipation
        • 5.2.3.3. Dyssynergic Constipation
      • 5.2.4. Global Constipation Treatment Region
        • 5.2.4.1. South America
          • 5.2.4.1.1. Brazil
          • 5.2.4.1.2. Argentina
          • 5.2.4.1.3. Rest of South America
        • 5.2.4.2. Asia Pacific
          • 5.2.4.2.1. China
          • 5.2.4.2.2. Japan
          • 5.2.4.2.3. India
          • 5.2.4.2.4. South Korea
          • 5.2.4.2.5. Taiwan
          • 5.2.4.2.6. Australia
          • 5.2.4.2.7. Rest of Asia-Pacific
        • 5.2.4.3. Europe
          • 5.2.4.3.1. Germany
          • 5.2.4.3.2. France
          • 5.2.4.3.3. Italy
          • 5.2.4.3.4. United Kingdom
          • 5.2.4.3.5. Netherlands
          • 5.2.4.3.6. Rest of Europe
        • 5.2.4.4. MEA
          • 5.2.4.4.1. Middle East
          • 5.2.4.4.2. Africa
        • 5.2.4.5. North America
          • 5.2.4.5.1. United States
          • 5.2.4.5.2. Canada
          • 5.2.4.5.3. Mexico
  • 6. Constipation Treatment: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2023)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. AstraZeneca (United Kingdom)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Bayer AG (Germany)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Sanofi (France)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Sucampo Pharmaceuticals, Inc. (United States)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Takeda Pharmaceuticals Company Limited (India)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Ironwood Pharmaceuticals, Inc. (United States)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Bausch Health (Canada)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Abbott Laboratories (United States)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Cosmo Pharmaceuticals NV (Ireland)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Synergy Pharmaceuticals, Inc. (United States)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
  • 7. Global Constipation Treatment Sale, by Application, Medication, Constipation and Region (value) (2025-2030)
    • 7.1. Introduction
    • 7.2. Global Constipation Treatment (Value)
      • 7.2.1. Global Constipation Treatment by: Application (Value)
        • 7.2.1.1. Infants
        • 7.2.1.2. Children
      • 7.2.2. Global Constipation Treatment by: Medication (Value)
        • 7.2.2.1. Opioids
        • 7.2.2.2. Vitamin Supplements
        • 7.2.2.3. Antiemetics
        • 7.2.2.4. Drugs
        • 7.2.2.5. Antacids
        • 7.2.2.6. Diuretics
      • 7.2.3. Global Constipation Treatment by: Constipation (Value)
        • 7.2.3.1. Normal Transit Constipation
        • 7.2.3.2. Slow Transit Constipation
        • 7.2.3.3. Dyssynergic Constipation
      • 7.2.4. Global Constipation Treatment Region
        • 7.2.4.1. South America
          • 7.2.4.1.1. Brazil
          • 7.2.4.1.2. Argentina
          • 7.2.4.1.3. Rest of South America
        • 7.2.4.2. Asia Pacific
          • 7.2.4.2.1. China
          • 7.2.4.2.2. Japan
          • 7.2.4.2.3. India
          • 7.2.4.2.4. South Korea
          • 7.2.4.2.5. Taiwan
          • 7.2.4.2.6. Australia
          • 7.2.4.2.7. Rest of Asia-Pacific
        • 7.2.4.3. Europe
          • 7.2.4.3.1. Germany
          • 7.2.4.3.2. France
          • 7.2.4.3.3. Italy
          • 7.2.4.3.4. United Kingdom
          • 7.2.4.3.5. Netherlands
          • 7.2.4.3.6. Rest of Europe
        • 7.2.4.4. MEA
          • 7.2.4.4.1. Middle East
          • 7.2.4.4.2. Africa
        • 7.2.4.5. North America
          • 7.2.4.5.1. United States
          • 7.2.4.5.2. Canada
          • 7.2.4.5.3. Mexico
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Constipation Treatment: by Application(USD Million)
  • Table 2. Constipation Treatment Infants , by Region USD Million (2018-2023)
  • Table 3. Constipation Treatment Children , by Region USD Million (2018-2023)
  • Table 4. Constipation Treatment: by Medication(USD Million)
  • Table 5. Constipation Treatment Opioids , by Region USD Million (2018-2023)
  • Table 6. Constipation Treatment Vitamin Supplements , by Region USD Million (2018-2023)
  • Table 7. Constipation Treatment Antiemetics , by Region USD Million (2018-2023)
  • Table 8. Constipation Treatment Drugs , by Region USD Million (2018-2023)
  • Table 9. Constipation Treatment Antacids , by Region USD Million (2018-2023)
  • Table 10. Constipation Treatment Diuretics , by Region USD Million (2018-2023)
  • Table 11. Constipation Treatment: by Constipation(USD Million)
  • Table 12. Constipation Treatment Normal Transit Constipation , by Region USD Million (2018-2023)
  • Table 13. Constipation Treatment Slow Transit Constipation , by Region USD Million (2018-2023)
  • Table 14. Constipation Treatment Dyssynergic Constipation , by Region USD Million (2018-2023)
  • Table 15. South America Constipation Treatment, by Country USD Million (2018-2023)
  • Table 16. South America Constipation Treatment, by Application USD Million (2018-2023)
  • Table 17. South America Constipation Treatment, by Medication USD Million (2018-2023)
  • Table 18. South America Constipation Treatment, by Constipation USD Million (2018-2023)
  • Table 19. Brazil Constipation Treatment, by Application USD Million (2018-2023)
  • Table 20. Brazil Constipation Treatment, by Medication USD Million (2018-2023)
  • Table 21. Brazil Constipation Treatment, by Constipation USD Million (2018-2023)
  • Table 22. Argentina Constipation Treatment, by Application USD Million (2018-2023)
  • Table 23. Argentina Constipation Treatment, by Medication USD Million (2018-2023)
  • Table 24. Argentina Constipation Treatment, by Constipation USD Million (2018-2023)
  • Table 25. Rest of South America Constipation Treatment, by Application USD Million (2018-2023)
  • Table 26. Rest of South America Constipation Treatment, by Medication USD Million (2018-2023)
  • Table 27. Rest of South America Constipation Treatment, by Constipation USD Million (2018-2023)
  • Table 28. Asia Pacific Constipation Treatment, by Country USD Million (2018-2023)
  • Table 29. Asia Pacific Constipation Treatment, by Application USD Million (2018-2023)
  • Table 30. Asia Pacific Constipation Treatment, by Medication USD Million (2018-2023)
  • Table 31. Asia Pacific Constipation Treatment, by Constipation USD Million (2018-2023)
  • Table 32. China Constipation Treatment, by Application USD Million (2018-2023)
  • Table 33. China Constipation Treatment, by Medication USD Million (2018-2023)
  • Table 34. China Constipation Treatment, by Constipation USD Million (2018-2023)
  • Table 35. Japan Constipation Treatment, by Application USD Million (2018-2023)
  • Table 36. Japan Constipation Treatment, by Medication USD Million (2018-2023)
  • Table 37. Japan Constipation Treatment, by Constipation USD Million (2018-2023)
  • Table 38. India Constipation Treatment, by Application USD Million (2018-2023)
  • Table 39. India Constipation Treatment, by Medication USD Million (2018-2023)
  • Table 40. India Constipation Treatment, by Constipation USD Million (2018-2023)
  • Table 41. South Korea Constipation Treatment, by Application USD Million (2018-2023)
  • Table 42. South Korea Constipation Treatment, by Medication USD Million (2018-2023)
  • Table 43. South Korea Constipation Treatment, by Constipation USD Million (2018-2023)
  • Table 44. Taiwan Constipation Treatment, by Application USD Million (2018-2023)
  • Table 45. Taiwan Constipation Treatment, by Medication USD Million (2018-2023)
  • Table 46. Taiwan Constipation Treatment, by Constipation USD Million (2018-2023)
  • Table 47. Australia Constipation Treatment, by Application USD Million (2018-2023)
  • Table 48. Australia Constipation Treatment, by Medication USD Million (2018-2023)
  • Table 49. Australia Constipation Treatment, by Constipation USD Million (2018-2023)
  • Table 50. Rest of Asia-Pacific Constipation Treatment, by Application USD Million (2018-2023)
  • Table 51. Rest of Asia-Pacific Constipation Treatment, by Medication USD Million (2018-2023)
  • Table 52. Rest of Asia-Pacific Constipation Treatment, by Constipation USD Million (2018-2023)
  • Table 53. Europe Constipation Treatment, by Country USD Million (2018-2023)
  • Table 54. Europe Constipation Treatment, by Application USD Million (2018-2023)
  • Table 55. Europe Constipation Treatment, by Medication USD Million (2018-2023)
  • Table 56. Europe Constipation Treatment, by Constipation USD Million (2018-2023)
  • Table 57. Germany Constipation Treatment, by Application USD Million (2018-2023)
  • Table 58. Germany Constipation Treatment, by Medication USD Million (2018-2023)
  • Table 59. Germany Constipation Treatment, by Constipation USD Million (2018-2023)
  • Table 60. France Constipation Treatment, by Application USD Million (2018-2023)
  • Table 61. France Constipation Treatment, by Medication USD Million (2018-2023)
  • Table 62. France Constipation Treatment, by Constipation USD Million (2018-2023)
  • Table 63. Italy Constipation Treatment, by Application USD Million (2018-2023)
  • Table 64. Italy Constipation Treatment, by Medication USD Million (2018-2023)
  • Table 65. Italy Constipation Treatment, by Constipation USD Million (2018-2023)
  • Table 66. United Kingdom Constipation Treatment, by Application USD Million (2018-2023)
  • Table 67. United Kingdom Constipation Treatment, by Medication USD Million (2018-2023)
  • Table 68. United Kingdom Constipation Treatment, by Constipation USD Million (2018-2023)
  • Table 69. Netherlands Constipation Treatment, by Application USD Million (2018-2023)
  • Table 70. Netherlands Constipation Treatment, by Medication USD Million (2018-2023)
  • Table 71. Netherlands Constipation Treatment, by Constipation USD Million (2018-2023)
  • Table 72. Rest of Europe Constipation Treatment, by Application USD Million (2018-2023)
  • Table 73. Rest of Europe Constipation Treatment, by Medication USD Million (2018-2023)
  • Table 74. Rest of Europe Constipation Treatment, by Constipation USD Million (2018-2023)
  • Table 75. MEA Constipation Treatment, by Country USD Million (2018-2023)
  • Table 76. MEA Constipation Treatment, by Application USD Million (2018-2023)
  • Table 77. MEA Constipation Treatment, by Medication USD Million (2018-2023)
  • Table 78. MEA Constipation Treatment, by Constipation USD Million (2018-2023)
  • Table 79. Middle East Constipation Treatment, by Application USD Million (2018-2023)
  • Table 80. Middle East Constipation Treatment, by Medication USD Million (2018-2023)
  • Table 81. Middle East Constipation Treatment, by Constipation USD Million (2018-2023)
  • Table 82. Africa Constipation Treatment, by Application USD Million (2018-2023)
  • Table 83. Africa Constipation Treatment, by Medication USD Million (2018-2023)
  • Table 84. Africa Constipation Treatment, by Constipation USD Million (2018-2023)
  • Table 85. North America Constipation Treatment, by Country USD Million (2018-2023)
  • Table 86. North America Constipation Treatment, by Application USD Million (2018-2023)
  • Table 87. North America Constipation Treatment, by Medication USD Million (2018-2023)
  • Table 88. North America Constipation Treatment, by Constipation USD Million (2018-2023)
  • Table 89. United States Constipation Treatment, by Application USD Million (2018-2023)
  • Table 90. United States Constipation Treatment, by Medication USD Million (2018-2023)
  • Table 91. United States Constipation Treatment, by Constipation USD Million (2018-2023)
  • Table 92. Canada Constipation Treatment, by Application USD Million (2018-2023)
  • Table 93. Canada Constipation Treatment, by Medication USD Million (2018-2023)
  • Table 94. Canada Constipation Treatment, by Constipation USD Million (2018-2023)
  • Table 95. Mexico Constipation Treatment, by Application USD Million (2018-2023)
  • Table 96. Mexico Constipation Treatment, by Medication USD Million (2018-2023)
  • Table 97. Mexico Constipation Treatment, by Constipation USD Million (2018-2023)
  • Table 98. Company Basic Information, Sales Area and Its Competitors
  • Table 99. Company Basic Information, Sales Area and Its Competitors
  • Table 100. Company Basic Information, Sales Area and Its Competitors
  • Table 101. Company Basic Information, Sales Area and Its Competitors
  • Table 102. Company Basic Information, Sales Area and Its Competitors
  • Table 103. Company Basic Information, Sales Area and Its Competitors
  • Table 104. Company Basic Information, Sales Area and Its Competitors
  • Table 105. Company Basic Information, Sales Area and Its Competitors
  • Table 106. Company Basic Information, Sales Area and Its Competitors
  • Table 107. Company Basic Information, Sales Area and Its Competitors
  • Table 108. Constipation Treatment: by Application(USD Million)
  • Table 109. Constipation Treatment Infants , by Region USD Million (2025-2030)
  • Table 110. Constipation Treatment Children , by Region USD Million (2025-2030)
  • Table 111. Constipation Treatment: by Medication(USD Million)
  • Table 112. Constipation Treatment Opioids , by Region USD Million (2025-2030)
  • Table 113. Constipation Treatment Vitamin Supplements , by Region USD Million (2025-2030)
  • Table 114. Constipation Treatment Antiemetics , by Region USD Million (2025-2030)
  • Table 115. Constipation Treatment Drugs , by Region USD Million (2025-2030)
  • Table 116. Constipation Treatment Antacids , by Region USD Million (2025-2030)
  • Table 117. Constipation Treatment Diuretics , by Region USD Million (2025-2030)
  • Table 118. Constipation Treatment: by Constipation(USD Million)
  • Table 119. Constipation Treatment Normal Transit Constipation , by Region USD Million (2025-2030)
  • Table 120. Constipation Treatment Slow Transit Constipation , by Region USD Million (2025-2030)
  • Table 121. Constipation Treatment Dyssynergic Constipation , by Region USD Million (2025-2030)
  • Table 122. South America Constipation Treatment, by Country USD Million (2025-2030)
  • Table 123. South America Constipation Treatment, by Application USD Million (2025-2030)
  • Table 124. South America Constipation Treatment, by Medication USD Million (2025-2030)
  • Table 125. South America Constipation Treatment, by Constipation USD Million (2025-2030)
  • Table 126. Brazil Constipation Treatment, by Application USD Million (2025-2030)
  • Table 127. Brazil Constipation Treatment, by Medication USD Million (2025-2030)
  • Table 128. Brazil Constipation Treatment, by Constipation USD Million (2025-2030)
  • Table 129. Argentina Constipation Treatment, by Application USD Million (2025-2030)
  • Table 130. Argentina Constipation Treatment, by Medication USD Million (2025-2030)
  • Table 131. Argentina Constipation Treatment, by Constipation USD Million (2025-2030)
  • Table 132. Rest of South America Constipation Treatment, by Application USD Million (2025-2030)
  • Table 133. Rest of South America Constipation Treatment, by Medication USD Million (2025-2030)
  • Table 134. Rest of South America Constipation Treatment, by Constipation USD Million (2025-2030)
  • Table 135. Asia Pacific Constipation Treatment, by Country USD Million (2025-2030)
  • Table 136. Asia Pacific Constipation Treatment, by Application USD Million (2025-2030)
  • Table 137. Asia Pacific Constipation Treatment, by Medication USD Million (2025-2030)
  • Table 138. Asia Pacific Constipation Treatment, by Constipation USD Million (2025-2030)
  • Table 139. China Constipation Treatment, by Application USD Million (2025-2030)
  • Table 140. China Constipation Treatment, by Medication USD Million (2025-2030)
  • Table 141. China Constipation Treatment, by Constipation USD Million (2025-2030)
  • Table 142. Japan Constipation Treatment, by Application USD Million (2025-2030)
  • Table 143. Japan Constipation Treatment, by Medication USD Million (2025-2030)
  • Table 144. Japan Constipation Treatment, by Constipation USD Million (2025-2030)
  • Table 145. India Constipation Treatment, by Application USD Million (2025-2030)
  • Table 146. India Constipation Treatment, by Medication USD Million (2025-2030)
  • Table 147. India Constipation Treatment, by Constipation USD Million (2025-2030)
  • Table 148. South Korea Constipation Treatment, by Application USD Million (2025-2030)
  • Table 149. South Korea Constipation Treatment, by Medication USD Million (2025-2030)
  • Table 150. South Korea Constipation Treatment, by Constipation USD Million (2025-2030)
  • Table 151. Taiwan Constipation Treatment, by Application USD Million (2025-2030)
  • Table 152. Taiwan Constipation Treatment, by Medication USD Million (2025-2030)
  • Table 153. Taiwan Constipation Treatment, by Constipation USD Million (2025-2030)
  • Table 154. Australia Constipation Treatment, by Application USD Million (2025-2030)
  • Table 155. Australia Constipation Treatment, by Medication USD Million (2025-2030)
  • Table 156. Australia Constipation Treatment, by Constipation USD Million (2025-2030)
  • Table 157. Rest of Asia-Pacific Constipation Treatment, by Application USD Million (2025-2030)
  • Table 158. Rest of Asia-Pacific Constipation Treatment, by Medication USD Million (2025-2030)
  • Table 159. Rest of Asia-Pacific Constipation Treatment, by Constipation USD Million (2025-2030)
  • Table 160. Europe Constipation Treatment, by Country USD Million (2025-2030)
  • Table 161. Europe Constipation Treatment, by Application USD Million (2025-2030)
  • Table 162. Europe Constipation Treatment, by Medication USD Million (2025-2030)
  • Table 163. Europe Constipation Treatment, by Constipation USD Million (2025-2030)
  • Table 164. Germany Constipation Treatment, by Application USD Million (2025-2030)
  • Table 165. Germany Constipation Treatment, by Medication USD Million (2025-2030)
  • Table 166. Germany Constipation Treatment, by Constipation USD Million (2025-2030)
  • Table 167. France Constipation Treatment, by Application USD Million (2025-2030)
  • Table 168. France Constipation Treatment, by Medication USD Million (2025-2030)
  • Table 169. France Constipation Treatment, by Constipation USD Million (2025-2030)
  • Table 170. Italy Constipation Treatment, by Application USD Million (2025-2030)
  • Table 171. Italy Constipation Treatment, by Medication USD Million (2025-2030)
  • Table 172. Italy Constipation Treatment, by Constipation USD Million (2025-2030)
  • Table 173. United Kingdom Constipation Treatment, by Application USD Million (2025-2030)
  • Table 174. United Kingdom Constipation Treatment, by Medication USD Million (2025-2030)
  • Table 175. United Kingdom Constipation Treatment, by Constipation USD Million (2025-2030)
  • Table 176. Netherlands Constipation Treatment, by Application USD Million (2025-2030)
  • Table 177. Netherlands Constipation Treatment, by Medication USD Million (2025-2030)
  • Table 178. Netherlands Constipation Treatment, by Constipation USD Million (2025-2030)
  • Table 179. Rest of Europe Constipation Treatment, by Application USD Million (2025-2030)
  • Table 180. Rest of Europe Constipation Treatment, by Medication USD Million (2025-2030)
  • Table 181. Rest of Europe Constipation Treatment, by Constipation USD Million (2025-2030)
  • Table 182. MEA Constipation Treatment, by Country USD Million (2025-2030)
  • Table 183. MEA Constipation Treatment, by Application USD Million (2025-2030)
  • Table 184. MEA Constipation Treatment, by Medication USD Million (2025-2030)
  • Table 185. MEA Constipation Treatment, by Constipation USD Million (2025-2030)
  • Table 186. Middle East Constipation Treatment, by Application USD Million (2025-2030)
  • Table 187. Middle East Constipation Treatment, by Medication USD Million (2025-2030)
  • Table 188. Middle East Constipation Treatment, by Constipation USD Million (2025-2030)
  • Table 189. Africa Constipation Treatment, by Application USD Million (2025-2030)
  • Table 190. Africa Constipation Treatment, by Medication USD Million (2025-2030)
  • Table 191. Africa Constipation Treatment, by Constipation USD Million (2025-2030)
  • Table 192. North America Constipation Treatment, by Country USD Million (2025-2030)
  • Table 193. North America Constipation Treatment, by Application USD Million (2025-2030)
  • Table 194. North America Constipation Treatment, by Medication USD Million (2025-2030)
  • Table 195. North America Constipation Treatment, by Constipation USD Million (2025-2030)
  • Table 196. United States Constipation Treatment, by Application USD Million (2025-2030)
  • Table 197. United States Constipation Treatment, by Medication USD Million (2025-2030)
  • Table 198. United States Constipation Treatment, by Constipation USD Million (2025-2030)
  • Table 199. Canada Constipation Treatment, by Application USD Million (2025-2030)
  • Table 200. Canada Constipation Treatment, by Medication USD Million (2025-2030)
  • Table 201. Canada Constipation Treatment, by Constipation USD Million (2025-2030)
  • Table 202. Mexico Constipation Treatment, by Application USD Million (2025-2030)
  • Table 203. Mexico Constipation Treatment, by Medication USD Million (2025-2030)
  • Table 204. Mexico Constipation Treatment, by Constipation USD Million (2025-2030)
  • Table 205. Research Programs/Design for This Report
  • Table 206. Key Data Information from Secondary Sources
  • Table 207. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Constipation Treatment: by Application USD Million (2018-2023)
  • Figure 5. Global Constipation Treatment: by Medication USD Million (2018-2023)
  • Figure 6. Global Constipation Treatment: by Constipation USD Million (2018-2023)
  • Figure 7. South America Constipation Treatment Share (%), by Country
  • Figure 8. Asia Pacific Constipation Treatment Share (%), by Country
  • Figure 9. Europe Constipation Treatment Share (%), by Country
  • Figure 10. MEA Constipation Treatment Share (%), by Country
  • Figure 11. North America Constipation Treatment Share (%), by Country
  • Figure 12. Global Constipation Treatment share by Players 2023 (%)
  • Figure 13. Global Constipation Treatment share by Players (Top 3) 2023(%)
  • Figure 14. Global Constipation Treatment share by Players (Top 5) 2023(%)
  • Figure 15. BCG Matrix for key Companies
  • Figure 16. AstraZeneca (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 17. AstraZeneca (United Kingdom) Revenue: by Geography 2023
  • Figure 18. Bayer AG (Germany) Revenue, Net Income and Gross profit
  • Figure 19. Bayer AG (Germany) Revenue: by Geography 2023
  • Figure 20. Sanofi (France) Revenue, Net Income and Gross profit
  • Figure 21. Sanofi (France) Revenue: by Geography 2023
  • Figure 22. Sucampo Pharmaceuticals, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 23. Sucampo Pharmaceuticals, Inc. (United States) Revenue: by Geography 2023
  • Figure 24. Takeda Pharmaceuticals Company Limited (India) Revenue, Net Income and Gross profit
  • Figure 25. Takeda Pharmaceuticals Company Limited (India) Revenue: by Geography 2023
  • Figure 26. Ironwood Pharmaceuticals, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 27. Ironwood Pharmaceuticals, Inc. (United States) Revenue: by Geography 2023
  • Figure 28. Bausch Health (Canada) Revenue, Net Income and Gross profit
  • Figure 29. Bausch Health (Canada) Revenue: by Geography 2023
  • Figure 30. Abbott Laboratories (United States) Revenue, Net Income and Gross profit
  • Figure 31. Abbott Laboratories (United States) Revenue: by Geography 2023
  • Figure 32. Cosmo Pharmaceuticals NV (Ireland) Revenue, Net Income and Gross profit
  • Figure 33. Cosmo Pharmaceuticals NV (Ireland) Revenue: by Geography 2023
  • Figure 34. Synergy Pharmaceuticals, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 35. Synergy Pharmaceuticals, Inc. (United States) Revenue: by Geography 2023
  • Figure 36. Global Constipation Treatment: by Application USD Million (2025-2030)
  • Figure 37. Global Constipation Treatment: by Medication USD Million (2025-2030)
  • Figure 38. Global Constipation Treatment: by Constipation USD Million (2025-2030)
  • Figure 39. South America Constipation Treatment Share (%), by Country
  • Figure 40. Asia Pacific Constipation Treatment Share (%), by Country
  • Figure 41. Europe Constipation Treatment Share (%), by Country
  • Figure 42. MEA Constipation Treatment Share (%), by Country
  • Figure 43. North America Constipation Treatment Share (%), by Country
List of companies from research coverage that are profiled in the study
  • AstraZeneca (United Kingdom)
  • Bayer AG (Germany)
  • Sanofi (France)
  • Sucampo Pharmaceuticals, Inc. (United States)
  • Takeda Pharmaceuticals Company Limited (India)
  • Ironwood Pharmaceuticals, Inc. (United States)
  • Bausch Health (Canada)
  • Abbott Laboratories (United States)
  • Cosmo Pharmaceuticals NV (Ireland)
  • Synergy Pharmaceuticals, Inc. (United States)
Additional players considered in the study are as follows:
Prestige Brands Holdings, Inc. (United States) , Janssen Pharmaceutical Company (Belgium) , Shionogi & Co., Ltd. (Japan)
Select User Access Type

Key Highlights of Report


Apr 2024 167 Pages 83 Tables Base Year: 2023 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Constipation Treatment Quantitative research analysis
Global Constipation Treatment Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

The standard version of the report profiles players such as AstraZeneca (United Kingdom), Bayer AG (Germany), Sanofi (France), Sucampo Pharmaceuticals, Inc. (United States), Takeda Pharmaceuticals Company Limited (India), Ironwood Pharmaceuticals, Inc. (United States), Bausch Health (Canada), Abbott Laboratories (United States), Cosmo Pharmaceuticals NV (Ireland) and Synergy Pharmaceuticals, Inc. (United States) etc.
The Study can be customized subject to feasibility and data availability. Please connect with our sales representative for further information.
"Increasing Adoption of Laxatives Treatment Type " is seen as one of major influencing trends for Constipation Treatment Market during projected period 2023-2030.
The Constipation Treatment market study includes a random mix of players, including both market leaders and some top growing emerging players. Connect with our sales executive to get a complete company list in our research coverage.

Know More About Global Constipation Treatment Report?

Have a Query? Click Here

Other Related Reports

Bilirubin Blood Test Comprehensive Study by Type (Transcutaneous, Bench-top), Application (Disease Diagnose, Blood Routine Analysis, Disease Prevention, Others), End Use (Hospital, Clinic, Healthcare...
$ 3800
Clinical Laboratory Service Comprehensive Study by Application (Hematology, Urinalysis, Microbiology, Immunochemistry, Others), Tests (Blood Testing, Urine Testing, Oral Fluid Testing, Hair Testing, ...
$ 3450
Healthcare Claim Management Comprehensive Study by Type (Integrated Solutions, Standalone Solutions), Deployment Mode (Cloud-Based, On-Premise), Components (Software, Hardware, Services) Players and ...
$ 3500
Scoliosis Treatment Comprehensive Study by Type (Structural Scoliosis, Non-Structural Scoliosis), Treatment (Device, Surgery, Others) Players and Region - Global Market Outlook to 2030
$ 3500
Hereditary Cancer Testing Comprehensive Study by Type (Biopsy, Imaging, Others), Application (Breast Cancer, Ovarian Cancer, Colorectal Cancer, Others), End User (Diagnostic Laboratory, Hospitals, Ot...
$ 3500
Veterinary Healthcare Product Comprehensive Study by Type (Therapeutics {Vaccines, Parasiticides, Anti-infectives, Medical Feed Additives & Other Therapeutics}, Diagnostics {Immunodiagnostic Tests, M...
$ 3750